labcorp | INVITAE

ONCOLOGY

Improve your patients' care with our comprehensive hereditary cancer genetic testing

Gain valuable clinical care insights

With our simplified universal testing process, it's easier for you to:

- Identify and educate patients
- Order tests
- Disclose results

Find more information about hereditary cancer genetic testing related to:



ONCOLOGY

Deliver a more customized care approach for patients with cancer

Universal hereditary cancer genetic testing refers to testing all patients with cancer regardless of risk factors like age at diagnosis, family history of cancer, or stage of disease.

Potential benefits of universal hereditary cancer genetic testing[1-6]:

Healthcare providers

- Help identify patients who could benefit from testing.
- Personalize your care approach across cancer types.
- Increase access to and reduce disparities in hereditary cancer genetic testing.

Patients

- Receive information about cancer surveillance and prevention options and learn about potential opportunities for tailored therapies.
- Gain access to clinical trials.

Family members

- Gain access to family variant testing.
- Receive personalized guidance for cancer surveillance and prevention options.



Nearly 50% of disease-causing gene variants may be missed using restrictive testing guidelines and coverage, despite the many benefits of hereditary cancer genetic testing.[2,6-7]

ONCOLOGY

Multiple clinical guidelines recommend hereditary cancer genetic testing[9-11]

Despite research that shows universal hereditary cancer genetic testing leads to important changes in patient clinical management and growing guideline support,[2,4,5,7,12] this testing remains underutilized.[13]

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Hereditary cancer genetic testing is recommended for all patients with exocrine pancreatic or epithelial ovarian cancer, as well as metastatic, node-positive, high-risk, or very high-risk prostate cancer, and should be considered for all patients with colorectal cancer with absent or untested tumor MMR deficiency status.[9,10]

The American Society of Breast Surgeons

Recommends hereditary cancer genetic testing for all patients with breast cancer.[11]

Improve patient follow-through with our hereditary cancer genetic testing available in-office

Less than 50% of patients referred to another provider for testing follow through on submitting test samples.[12]

ONCOLOGY

By the numbers

2020 INTERCEPT study of inherited gene variants in **2,984** patients with solid tumor cancer

1 in 8 patients with cancer had an inherited gene variant associated with increased cancer risk[2]



28% of patients with the highest risk cancer gene variants had genetic test result-informed changes made to their medical management because of their genetic test results[2]

Among patients who experienced modifications to their medical management, changes included[2]:



targeted therapy



surgery



clinical trial initiation

BREAST CANCER

Hereditary cancer genetic testing is underutilized in breast cancer[13,14]

Hereditary cancer genetic testing can have meaningful clinical impacts.[5] It's recommended for all patients with breast cancer and for high-risk patients without a breast cancer diagnosis.[11,15]

Affected patients

The American Society of Breast Surgeons recommends offering hereditary cancer genetic testing to all patients with breast cancer.[1]

- **1 in 8** patients with breast cancer have an inherited gene variant associated with increased cancer risk[2,8]
- **>75%** of patients with breast cancer and an inherited cancer risk gene variant had changes to their clinical management[5]
- **73%** of patients with breast cancer remain untested[13,14]

Unaffected patients

The NCCN Guidelines® suggest that hereditary cancer genetic testing should be made available to women at high risk (including those with a strong family history of breast cancer or Ashkenazi Jewish ancestry) without a breast cancer diagnosis.[9]

- **1 in 4** women are eligible for hereditary cancer genetic testing[15]

Early identification can lead to improved survival rates when patients know their *BRCA* status before a breast cancer diagnosis.[16,17]

OVARIAN CANCER

Nearly 60% of patients with ovarian cancer don't receive recommended hereditary cancer genetic testing[13,18]

Genetic insights can change lives

1 in 5 patients with ovarian cancer have an inherited gene variant associated with increased cancer risk[2,19,20]

Over 30% of women with cancer risk gene variants have no family history of breast or ovarian cancer, highlighting the importance of hereditary cancer genetic testing for all patients with ovarian cancer[19]

Why it matters

Hereditary cancer genetic testing can uncover personalized treatment options that may improve outcomes—and may help prevent future cancers. For patients with gene variants, clinical care can include[1,2]:

- Targeted therapies
- Preventive surgeries
- Access to clinical trials
- Specialist referrals
- Family member testing and genetic counseling

Who should be tested

The NCCN Guidelines recommend hereditary cancer testing for all patients with epithelial ovarian cancer—as well as unaffected individuals who have a close relative with ovarian cancer and may be at high-risk to develop ovarian cancer themselves.[9]

COLORECTAL CANCER

Hereditary cancer genetic testing for patients with colorectal cancer can help tailor their treatment journey[9,21,22]— yet just 6% of patients receive it[13]

Genetic insights can guide care

- **1 in 7** patients with colorectal cancer have an inherited gene variant that increases cancer risk.[21-23]
- Despite this, testing remains underutilized—missing opportunities for more informed care.

Why it matters

Clinically actionable results can help[10,21-23]:

- Assess future risk of colorectal and other cancers
- Inform surgical decisions for patients with Lynch syndrome
- Shape treatment strategies for advanced disease
- Identify family members at risk for cancer and guide the starting age and frequency of screenings, like colonoscopies

Who should be tested

While NCCN Guidelines recommend considering hereditary cancer testing for patients with absent or untested tumor MMR deficiency,[10] emerging research supports expanding testing to all patients with colorectal cancer.[21-24]

Order hereditary cancer genetic testing for your patients with colorectal cancer to uncover critical insights and enable personalized care.

PANCREATIC CANCER

Hereditary cancer genetic testing can uncover personalized treatment options

Fewer than 6% of pancreatic cancer patients receive hereditary cancer genetic testing despite its potential to guide care.[13]

The value of identifying inherited gene variants

- **1 in 6** patients with pancreatic cancer have an inherited gene variant associated with cancer risk[25,26]
- Patients with cancer risk variants may benefit from targeted therapies and other tailored clinical management strategies.[25,26]
- Patients with inherited gene variants may experience better overall survival compared to those without.[26]

Why it matters

- Precision treatment planning
- Risk assessment for other cancers
- Family member testing and genetic counseling

Who should be tested

The NCCN Guidelines recommend hereditary cancer genetic testing for all patients with exocrine pancreatic cancer.[9]

Order hereditary cancer genetic testing to help deliver more personalized, informed care for your patients with pancreatic cancer.

PROSTATE CANCER

Hereditary cancer genetic testing is often underused—yet it could change the course of care

Only 1% of patients with prostate cancer receive hereditary cancer genetic testing.[13]

But the potential impact is significant[27]:

- **1 in 7** patients with prostate cancer have an inherited gene variant associated with increased cancer risk
- **81%** of inherited cancer risk gene variants in patients with prostate cancer are potentially clinically actionable

Why it matters

Hereditary cancer genetic testing can help[1,2]:

- Guide targeted therapy decisions
- Inform screening for other cancers
- Identify cancer risk in family members

Who should be tested

While the latest NCCN Guidelines recommend hereditary cancer genetic testing for all patients with metastatic, node-positive, high-risk, or very high-risk prostate cancer[9], the PROCLAIM trial provides evidence to support testing all patients with prostate cancer.[6,7]

Universal hereditary cancer genetic testing for patients with prostate cancer may help enhance patient care by identifying clinically actionable findings.[7,27]

Ensure you have the full picture with universal hereditary cancer genetic testing

Partner with us to expand access and improve care

Hereditary cancer genetic testing has the power to transform patient outcomes.[1,2] As your trusted genetics partner, we're here to help you integrate testing seamlessly into your practice.

Here's how we support you:

Streamlined, patient-friendly testing

We offer a fast, convenient process with:

- Point-of-care test ordering
- Personalized support to optimize your workflow
- Post-test genetic counseling for your patients—especially if you don't already work with a genetic counselor

Access to Gia®—your virtual genetics assistant

Gia® is a HIPAA-compliant, 24/7 clinical chatbot that:

- Collects detailed personal and family history
- Educates patients about genetic testing
- Simplifies the ordering process
- Can be customized to release results based on your preferences

Average turnaround time for Invitae hereditary cancer genetic testing is 10–21 days.

Affordable payment options and dedicated billing specialists

Invitae is part of Labcorp, an in-network laboratory with most major health plans. For patients with insurance, including Medicare/Medicaid, we bill all covered costs to their insurance provider at contracted rates. For uninsured patients, we have a number of options available to support them. Our dedicated billing specialists can help guide coverage options. Contact us at **LcGeneticsBilling@labcorp.com** or **833-941-0828**. Learn more at **invitae.com/billing**

References

1. Esplin ED, et al. *JCO Precis Oncol*. 2022:e2100516.
2. Samadder NJ, et al. *JAMA Oncol*. 2021;7(2):230–237.
3. Rezoug Z, et al. *JAMA Netw*. 2024;e2431427.
4. Shelton C, et al. *Ann Surg Oncol*. 2023;doi:10.1245/s10434-023-14394-3.
5. Whitworth PW, et al. *JAMA Netw Open*. 2022;5(9):e2232787.
6. Shore N, et al. *Eur Urol Oncol*. 2023;6(5):477–483.
7. Shore N et al. *J Urol*. 2024; 212(6):832-843.
8. Beitsch PD, et al. *J Clin Oncol*. 2019;37, 453–460.
9. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate V.1.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed September 8, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
10. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed September 8, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
11. Manahan ER, et al. *Ann Surg Oncol*. 2019;26(10):3025–3031.
12. DeFrancesco MS, et al. *Obstet Gynecol*. 2018;1132(5):1121–1129.
13. Kurian AW, et al. *JAMA*. 2023;330(1):43
14. Clark NM, et al. *Ann Surg Oncol*. 2023;30:1312–1326.
15. Nazareth S, et al. *Obstet Gynecol*. 2021;138(6):860–870.
16. Hadar T, et al. *JAMA Oncol*. 2020;6(9):1460–1463.
17. Lambertini M, et al. *J Clin Oncol*. 2025; JCO2401334.
18. Lau-Min KS, et al. *J Natl Compr Canc Netw*. 2023;21(4):351–358.
19. Walsh T, et al. *PNAS*. 2011;108(44):18032–7.
20. Norquist BM, et al. *JAMA Oncol*. 2016;2(4):482–490.
21. Coughlin SE, et al. *JCO Precis Oncol*. 2022:e2200517.
22. Uson Jr PLS, et al. *Clin Gastroenterol and Hepatology*. 2021;e508 – e528.
23. Muller C, et al. *Gastroenterology*. 2020;158 (2):441-446.
24. Moretz C, et al. *JAMA Netw Open*. 2022;5(10):e2238167.
25. Golan T, et al. *NEJM*. 2019;381(4):317–327.
26. Uson Jr PLS, et al. *Clin Transl Gastroenterol*. 2021;12(10):e00414.
27. Choudry MM, et al. *J. Urol*. 2024; 212(4):590–9.

For more information on our testing options visit us online at **invitae.com/us/providers**

labcorp | INVITAE